305 related articles for article (PubMed ID: 26590715)
1. Drugging Chromatin in Cancer: Recent Advances and Novel Approaches.
Cai SF; Chen CW; Armstrong SA
Mol Cell; 2015 Nov; 60(4):561-70. PubMed ID: 26590715
[TBL] [Abstract][Full Text] [Related]
2. Targeting Epigenetics in Cancer.
Bennett RL; Licht JD
Annu Rev Pharmacol Toxicol; 2018 Jan; 58():187-207. PubMed ID: 28992434
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic targeting of chromatin: status and opportunities.
Siklos M; Kubicek S
FEBS J; 2022 Mar; 289(5):1276-1301. PubMed ID: 33982887
[TBL] [Abstract][Full Text] [Related]
4. Development and classes of epigenetic drugs for cancer.
Dhanak D; Jackson P
Biochem Biophys Res Commun; 2014 Dec; 455(1-2):58-69. PubMed ID: 25016182
[TBL] [Abstract][Full Text] [Related]
5. Chromatin-modifying agents in anti-cancer therapy.
Seidel C; Florean C; Schnekenburger M; Dicato M; Diederich M
Biochimie; 2012 Nov; 94(11):2264-79. PubMed ID: 22627380
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic drugs against cancer: an evolving landscape.
Di Costanzo A; Del Gaudio N; Migliaccio A; Altucci L
Arch Toxicol; 2014 Sep; 88(9):1651-68. PubMed ID: 25085708
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic targeting drugs potentiate chemotherapeutic effects in solid tumor therapy.
Li J; Hao D; Wang L; Wang H; Wang Y; Zhao Z; Li P; Deng C; Di LJ
Sci Rep; 2017 Jun; 7(1):4035. PubMed ID: 28642588
[TBL] [Abstract][Full Text] [Related]
8. Targeting Epigenetic Regulators with Covalent Small-Molecule Inhibitors.
Zhang Y; Rong D; Li B; Wang Y
J Med Chem; 2021 Jun; 64(12):7900-7925. PubMed ID: 33599482
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic therapy of cancer with histone deacetylase inhibitors.
Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
[TBL] [Abstract][Full Text] [Related]
10. Current and upcoming approaches to exploit the reversibility of epigenetic mutations in breast cancer.
Falahi F; van Kruchten M; Martinet N; Hospers GA; Rots MG
Breast Cancer Res; 2014 Jul; 16(4):412. PubMed ID: 25410383
[TBL] [Abstract][Full Text] [Related]
11. Clinical advances in targeting epigenetics for cancer therapy.
Feng S; De Carvalho DD
FEBS J; 2022 Mar; 289(5):1214-1239. PubMed ID: 33545740
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic perspectives on cancer chemotherapy response.
Liu MZ; McLeod HL; He FZ; Chen XP; Zhou HH; Shu Y; Zhang W
Pharmacogenomics; 2014 Apr; 15(5):699-715. PubMed ID: 24798726
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic opportunities and challenges in cancer.
Best JD; Carey N
Drug Discov Today; 2010 Jan; 15(1-2):65-70. PubMed ID: 19897050
[TBL] [Abstract][Full Text] [Related]
14. Unraveling the epigenetic code of cancer for therapy.
Smith LT; Otterson GA; Plass C
Trends Genet; 2007 Sep; 23(9):449-56. PubMed ID: 17681396
[TBL] [Abstract][Full Text] [Related]
15. Chromatin modifying agents - the cutting edge of anticancer therapy.
Kwa FA; Balcerczyk A; Licciardi P; El-Osta A; Karagiannis TC
Drug Discov Today; 2011 Jul; 16(13-14):543-7. PubMed ID: 21664485
[TBL] [Abstract][Full Text] [Related]
16. Targeting chromatin.
Nat Struct Mol Biol; 2019 Oct; 26(10):841. PubMed ID: 31582845
[No Abstract] [Full Text] [Related]
17. Targeting chromatin readers.
James LI; Frye SV
Clin Pharmacol Ther; 2013 Apr; 93(4):312-4. PubMed ID: 23403847
[TBL] [Abstract][Full Text] [Related]
18. Zebularine: a candidate for epigenetic cancer therapy.
Bradbury J
Drug Discov Today; 2004 Nov; 9(21):906-7. PubMed ID: 15501719
[TBL] [Abstract][Full Text] [Related]
19. The potential of DNA modifications as biomarkers and therapeutic targets in oncology.
Jankowska AM; Millward CL; Caldwell CW
Expert Rev Mol Diagn; 2015; 15(10):1325-37. PubMed ID: 26394702
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic therapy for solid tumors: from bench science to clinical trials.
Juo YY; Gong XJ; Mishra A; Cui X; Baylin SB; Azad NS; Ahuja N
Epigenomics; 2015; 7(2):215-35. PubMed ID: 25942532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
